Brought to you by 
Shire buys Dyax for $5.5bn
09 Sep 2020
Executive Summary
Shire PLC paid $5.5bn ($37.30 per share; a 36% premium) in cash to acquire Dyax Corp. Dyax shareholders may also receive a non-tradable contingent value right that will pay $4.00 in cash per share--about $646mm in total--upon approval (prior to the end of 2019) of its Phase III-ready plasma kallikrein (pKal) inhibitor DX2930 (lanadelumab) for prevention of Types 1 and 2 hereditary angioedema (HAE).
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Molecular Diversity
-
Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Shire buys Dyax for $5.5bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice